INCY · Incyte Corp
$117.68
+0.99 (+0.84%)
At close · Jul 24
Market Cap
$23.51B
Shares
199.78M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5.14B
+21.2%
FY2025
Net Income
$1.29B
+3845%
FY2025
Gross Margin
92.76%
+0.1pp
FY2025
Operating Margin
29.46%
+28pp
FY2025
Diluted EPS
$6.41
+4173.3%
FY2025
Operating Cash Flow
$1.41B
+321.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2030 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3B – $4B | $5.36B | $5.14BG | $4.24B | $3.7B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $753.75M | $511.5M | $354.95M | $297.06M | $94.46M | |
| — | $403.47M | $372.13M | $312.07M | $254.99M | $207M | $150.99M | $131.33M | $114.25M | $94.12M | $79.48M | $58.19M | $26.97M | $3M | $630K | $157K | — | |
| — | $4.96B | $4.77B | $3.93B | $3.44B | $3.19B | $2.84B | $2.54B | $2.04B | $1.79B | $1.46B | $1.05B | $726.78M | $508.49M | $354.32M | $296.9M | — | |
| — | — | 92.76% | 92.64% | 93.1% | 93.9% | 94.94% | 95.08% | 94.71% | 95% | 94.83% | 94.74% | 96.42% | 99.41% | 99.82% | 99.95% | — | |
| — | $2.13B | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B | $2.22B | $1.15B | $1.2B | $1.33B | $581.86M | $479.51M | $347.52M | $260.44M | $210.39M | $178.71M | |
| — | $1.38B | $1.38B | $1.24B | $1.16B | $1B | $739.56M | $516.92M | $468.71M | $434.41M | $366.41M | $303.25M | $196.61M | $165.77M | $109.98M | $85.36M | $58.22M | |
| — | — | $26.7M | $23.6M | $22.5M | $21.5M | $21.5M | $21.5M | $21.5M | $21.5M | $21.5M | — | — | — | $1.7M | — | — | |
| — | — | $93.29M | $89.25M | $82.66M | $67.86M | $57.84M | $51.81M | $54.53M | $54.97M | $52.18M | $58.43M | $44.88M | $41.41M | $29.21M | $29.98M | $26.99M | |
| — | $3.75B | $3.63B | $4.18B | $3.08B | $2.82B | $2.4B | $2.93B | $1.76B | $1.75B | $1.78B | $960.72M | $703.1M | $516.3M | $371.05M | $295.91M | $237.64M | |
| — | $1.61B | $1.51B | $61.37M | $620.53M | $579.44M | $585.78M | -$263.68M | $402.01M | $129.22M | -$243.73M | $145M | $50.65M | -$4.8M | -$16.1M | $1.15M | -$143.18M | |
| — | — | 29.46% | 1.45% | 16.79% | 17.07% | 19.62% | -9.89% | 18.62% | 6.87% | -15.87% | 13.11% | 6.72% | -0.94% | -4.54% | 0.39% | -151.59% | |
| — | — | $1.61B | $150.61M | $703.19M | $647.3M | $643.62M | -$211.87M | $456.54M | $184.19M | -$191.56M | $203.42M | $95.53M | $36.61M | $13.11M | $31.13M | -$116.19M | |
| — | $2.34M | $2.43M | $2.28M | $2.55M | $2.67M | $1.91M | $2.17M | $1.86M | $1.54M | $6.9M | $38.75M | $45.6M | $46.83M | $38.65M | $46.06M | $43.82M | |
| — | $116.36M | $105.6M | $128.71M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $19.79M | $25.11M | $12.81M | $172.35M | $39.93M | $10.65M | $23.21M | $52.18M | — | — | — | — | — | — | — | — | |
| — | $1.77B | $1.66B | $316.63M | $834.22M | $529.12M | $570.44M | -$232.22M | $486.79M | $115.35M | -$312.29M | $107.4M | $7.56M | -$48.55M | -$82.85M | -$44.15M | — | |
| — | $342.08M | $377.8M | $284.02M | $236.62M | $188.46M | -$378.14M | $63.48M | $39.89M | $5.85M | $852K | $3.18M | $1.03M | -$66K | $299K | $174K | — | |
| — | $1.43B | $1.29B | $32.62M | $597.6M | $340.66M | $948.58M | -$295.7M | $446.91M | $109.49M | — | — | — | — | — | — | — | |
| — | — | 25.03% | 0.77% | 16.17% | 10.04% | 31.76% | -11.09% | 20.7% | 5.82% | — | — | — | — | — | — | — | |
| — | $1.43B | $1.29B | $32.62M | $597.6M | $340.66M | $948.58M | -$295.7M | $446.91M | $109.49M | -$313.14M | $104.22M | $6.53M | -$48.48M | -$83.15M | -$44.32M | -$186.54M | |
| — | $1.46B | $1.33B | $6.39M | $595.64M | $375.18M | $944.49M | -$295.52M | $441.53M | $109.09M | -$317.27M | $102.15M | $3.91M | -$48.66M | -$83.03M | -$44.08M | -$186.88M | |
| USD/shares | — | — | $6.59 | $0.16 | $2.67 | $1.53 | $4.30 | -$1.36 | $2.08 | $0.52 | -$1.53 | $0.55 | $0.04 | -$0.22 | $0.14 | $0.14 | $0.26 |
| USD/shares | — | — | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | -$1.36 | $2.05 | $0.51 | -$1.53 | $0.54 | $0.03 | -$0.22 | $0.14 | $0.14 | $0.24 |
| shares | — | — | 195.2M | 207.11M | 223.63M | 222M | 220.43M | 218.07M | 214.91M | 212.38M | 204.58M | 187.87M | 179.6M | 167.95M | 148.4M | 131.71M | 125.36M |
| shares | — | — | 200.7M | 210.53M | 225.93M | 223.96M | 222.07M | 218.07M | 217.66M | 215.64M | 204.58M | 194.13M | 187.3M | 167.95M | 148.4M | 139.12M | 125.36M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $2B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
16.62×
Biotechnology median 7.07×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $5,141,242,000 | $4,241,217,000 | $3,695,649,000 | $3,394,635,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $4,799,941,000 | $3,974,567,000 | $3,514,873,000 | $3,200,000,000 | $2,900,000,000 | $2,600,000,000 | $2,100,000,000 | $1,800,000,000 |
| Europe | $323,734,000 | $260,437,000 | $175,866,000 | $147,000,000 | $124,100,000 | $105,000,000 | $90,000,000 | $79,900,000 |
| Other Countries | $17,567,000 | $6,213,000 | $4,910,000 | — | — | — | — | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $4,354,333,000 | $3,618,888,000 | $3,165,168,000 | $2,746,897,000 | $2,322,012,000 | $2,068,736,000 | — | $1,466,900,000 |
| JAKAFI | $3,092,515,000 | $2,792,107,000 | $2,593,732,000 | $2,409,225,000 | $2,134,508,000 | $1,937,850,000 | $1,684,968,000 | $1,386,964,000 |
| OPZELURA | $678,455,000 | $508,293,000 | $337,864,000 | $128,735,000 | $4,668,000 | $0 | — | — |
| Royalty | $636,909,000 | $579,329,000 | $523,481,000 | $482,738,000 | $569,255,000 | $392,966,000 | — | $234,780,000 |
| JAKAVI Royalty Revenues | $457,729,000 | $418,840,000 | $367,583,000 | $331,575,000 | $337,991,000 | $277,902,000 | $225,913,000 | $194,694,000 |
| NIKTIMVO | $151,636,000 | $0 | $0 | — | — | — | — | — |
| Milestone and Contract Revenues | $150,000,000 | $43,000,000 | $7,000,000 | $165,000,000 | $95,000,000 | — | — | — |
| Olumiant Royalty | $144,600,000 | $135,572,000 | $136,138,000 | $134,547,000 | $220,875,000 | $110,920,000 | — | $40,086,000 |
| MINJUVIMONJUVI | $144,578,000 | $119,236,000 | $37,057,000 | $19,654,000 | — | — | — | — |
| ICLUSIG | $134,071,000 | $114,319,000 | $111,623,000 | $105,838,000 | $109,395,000 | $105,002,000 | $89,954,000 | $79,936,000 |
| Pemazyre | $86,727,000 | $81,748,000 | $83,642,000 | $83,445,000 | $68,531,000 | $25,884,000 | $89,954,000 | — |
| ZYNYZ | $66,351,000 | $3,185,000 | $1,250,000 | $0 | $0 | — | — | — |
| TABRECTA Royalty Revenues | $26,702,000 | $22,746,000 | $17,793,000 | $15,411,000 | $10,389,000 | $4,144,000 | — | — |
| Other Product Royalty Revenues | $7,878,000 | $2,171,000 | $1,967,000 | — | — | — | — | — |
| Milestone and Contract Revenue | — | — | — | $165,000,000 | $95,000,000 | $205,000,000 | $77,500,000 | $180,000,000 |
| MINJUVI | — | — | $37,057,000 | $19,654,000 | $4,910,000 | $0 | — | — |
| PEMAZYRE Royalty Revenues | — | $2,171,000 | $1,967,000 | $1,205,000 | $0 | $0 | — | — |
| Product And Service Other | — | — | — | — | — | — | — | $203,000 |